Edition:
India

People: Intra-Cellular Therapies Inc (ITCI.OQ)

ITCI.OQ on NASDAQ Stock Exchange Global Select Market

20.91USD
1:30am IST
Change (% chg)

$0.33 (+1.60%)
Prev Close
$20.58
Open
$20.64
Day's High
$21.14
Day's Low
$20.41
Volume
265,411
Avg. Vol
275,074
52-wk High
$43.56
52-wk Low
$6.75

Neumann, Mark 

Mr. Mark Neumann is Executive Vice President, Chief Commercial Officer of the Company. Mr. Neumann has served as Executive Vice President, Chief Commercial Officer of the Company since October 2018. From June 2014 to October 2018, Mr. Neumann served in leadership positions at Amgen, most recently serving as Vice President, Global Marketing. Before Amgen, from February 2014 to June 2014 Mr. Neumann served in a leadership position at AstraZeneca. Before joining AstraZeneca, from June 1988 to February 2014, he served at Bristol Myers Squibb Company in positions of increasing responsibility, including commercial leadership roles. Mr. Neumann is a licensed CPA (inactive) and received his bachelor’s degree from Lafayette College.

Basic Compensation

Total Annual Compensation, USD 780,900
Restricted Stock Award, USD 799,991
Long-Term Incentive Plans, USD --
All Other, USD 933,446
Fiscal Year Total, USD 2,514,340

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Lawrence Hineline

2,193,530

Michael Halstead

2,337,450

Mark Neumann

2,514,340

Andrew Satlin

2,644,820

Robert Davis

2,128,540

John Bardi

--
As Of  31 Dec 2019